BioXcel Therapeutics, which is developing new uses of drugs to treat neurological disorders and cancer, raised $60 million by offering 5.5 million shares at $11, the low end of the range of $11 to $13. BioXcel Therapeutics plans to list on the Nasdaq under the symbol BTAI. Barclays, UBS Investment Bank and BMO Capital Markets acted as lead managers on the deal.
